ID22933A - Fomulasi protien c terakivasi - Google Patents

Fomulasi protien c terakivasi

Info

Publication number
ID22933A
ID22933A IDW991133A ID991133A ID22933A ID 22933 A ID22933 A ID 22933A ID W991133 A IDW991133 A ID W991133A ID 991133 A ID991133 A ID 991133A ID 22933 A ID22933 A ID 22933A
Authority
ID
Indonesia
Prior art keywords
protient
fomulation
protient fomulation
Prior art date
Application number
IDW991133A
Other languages
English (en)
Indonesian (id)
Inventor
Andrew David Carlson
Theodore Arsay Sheliga
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ID22933A publication Critical patent/ID22933A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IDW991133A 1997-04-28 1998-04-24 Fomulasi protien c terakivasi ID22933A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4525597P 1997-04-28 1997-04-28

Publications (1)

Publication Number Publication Date
ID22933A true ID22933A (id) 1999-12-16

Family

ID=21936854

Family Applications (2)

Application Number Title Priority Date Filing Date
IDW991133A ID22933A (id) 1997-04-28 1998-04-24 Fomulasi protien c terakivasi
IDW991254A ID23172A (id) 1997-04-28 1998-04-24 Metode yang diperbaiki untuk pengolahan protein c teraktivasi

Family Applications After (1)

Application Number Title Priority Date Filing Date
IDW991254A ID23172A (id) 1997-04-28 1998-04-24 Metode yang diperbaiki untuk pengolahan protein c teraktivasi

Country Status (34)

Country Link
US (4) US6162629A (enExample)
EP (2) EP0875252B1 (enExample)
JP (2) JP4383546B2 (enExample)
KR (2) KR100450856B1 (enExample)
CN (2) CN1227025C (enExample)
AR (2) AR015598A1 (enExample)
AT (1) ATE285788T1 (enExample)
AU (2) AU740753C (enExample)
BR (2) BR9809292A (enExample)
CA (2) CA2287267C (enExample)
CO (2) CO4950523A1 (enExample)
CZ (1) CZ298429B6 (enExample)
DE (1) DE69828330T2 (enExample)
DK (1) DK0875252T3 (enExample)
EA (2) EA002149B1 (enExample)
EG (1) EG23685A (enExample)
ES (1) ES2234072T3 (enExample)
HU (2) HU224826B1 (enExample)
ID (2) ID22933A (enExample)
IL (2) IL132502A0 (enExample)
IN (2) IN183798B (enExample)
MY (2) MY118591A (enExample)
NO (2) NO995134L (enExample)
NZ (2) NZ500346A (enExample)
PE (2) PE84799A1 (enExample)
PL (2) PL195642B1 (enExample)
PT (1) PT875252E (enExample)
SI (1) SI0875252T1 (enExample)
SV (2) SV1998000050A (enExample)
TR (2) TR199902631T2 (enExample)
TW (2) TWI242443B (enExample)
UA (2) UA55448C2 (enExample)
WO (2) WO1998048822A1 (enExample)
ZA (2) ZA983496B (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR015598A1 (es) 1997-04-28 2001-05-16 Lilly Co Eli FORMULACIoN LIOFILIZADA QUE COMPRENDE PROTEíNA C ACTIVADA, SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO Y FORMA DE DOSIS UNITARIA QUE LA COMPRENDE.
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
ES2259248T3 (es) * 1998-11-13 2006-09-16 Eli Lilly And Company Uso de la proteina c humana para la preparacion de un medicamento para el tratamiento de trombocitopenia inducida por heparina.
IL142220A0 (en) * 1998-11-20 2002-03-10 Lilly Co Eli Method of treating viral hemorrhagic fever
ATE232739T1 (de) * 1998-11-23 2003-03-15 Lilly Co Eli Protein c zur behandlung von sichelzellanämie und thalassämie
CA2351555A1 (en) * 1998-12-10 2000-06-15 Eli Lilly And Company Method of treating thrombocytopenic purpura and hemolytic uremic syndrome
US6758938B1 (en) * 1999-08-31 2004-07-06 Micron Technology, Inc. Delivery of dissolved ozone
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
JP2004511428A (ja) * 2000-05-24 2004-04-15 イーライ・リリー・アンド・カンパニー 凝固亢進状態を処置するための製剤および方法
ES2309167T3 (es) 2001-02-19 2008-12-16 Merck Patent Gmbh Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida.
US7101982B2 (en) * 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
US20030055003A1 (en) * 2001-07-19 2003-03-20 David Bar-Or Use of copper chelators to inhibit the inactivation of protein C
US6838432B2 (en) 2001-09-19 2005-01-04 Oklahoma Medical Research Foundation Treatment of sepsis with TAFI
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
PL374506A1 (en) 2001-10-15 2005-10-31 Chiron Corporation Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
AU2003213146A1 (en) * 2002-03-08 2003-09-22 Eli Lilly And Company Activated protein c formulations
CA2490342C (en) 2002-06-21 2015-06-16 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
CA2502378A1 (en) * 2002-10-29 2004-05-13 Alza Corporation Stabilized, solid-state polypeptide particles
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
EP1641487B1 (en) * 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
MXPA06010587A (es) * 2004-03-17 2007-03-29 Chiron Corp Tratamiento de neumonia severa adquirida en comunidad por administracion del inhibidor de la via del factor tisular (tfpi).
WO2006014839A2 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
AU2006261555A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor lll polymorphisms associated with prediction of subject outcome and response to therapy
EP2029740B1 (en) * 2006-05-31 2012-06-20 Genzyme Corporation Use of polysaccharides for promotion of enzymatic activity
EP2041338A4 (en) * 2006-06-09 2009-09-30 Univ British Columbia INTERFERON GAMMA POLYMORPHISMS AS INDICATORS OF RESULT IN SERIOUSLY SICK SUBJECTS
JP5179521B2 (ja) * 2007-03-05 2013-04-10 カディラ・ヘルスケア・リミテッド ペグ‐インターフェロンアルファ接合体および凍結保護剤としてラフィノースを含む組成物
CA2681752A1 (en) * 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
CN101969971A (zh) * 2007-11-30 2011-02-09 雅培制药有限公司 蛋白制剂及其制备方法
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2712057A1 (en) * 2008-01-15 2009-07-23 The University Of British Columbia Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
JP2012510468A (ja) * 2008-11-28 2012-05-10 アボット・ラボラトリーズ 安定な抗体組成物およびこれを安定させるための方法
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2834635A4 (en) 2012-04-03 2015-09-02 Smiths Medical Asd Inc COMPOSITIONS WITH A HEPARINE ACCUMULATIVE AND METHOD THEREFOR
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
CN104394883B (zh) 2012-07-04 2017-05-31 悉尼大学 炎性皮肤病症的治疗
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
PT3137102T (pt) 2014-04-16 2021-09-28 Zz Biotech Llc Apc para utilização no tratamento de cicatrização cutânea anormal
EP3131572B1 (en) 2014-04-16 2021-07-14 ZZ Biotech LLC Apc analogue for use in wound healing
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
AU2017299374B2 (en) 2016-06-01 2021-05-27 Servier IP UK Limited Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
JPH01226900A (ja) * 1988-03-08 1989-09-11 Green Cross Corp:The プロテインｃの精製方法
DE3823519A1 (de) * 1988-07-12 1990-01-18 Basf Ag Verfahren zur reinigung von aktiviertem protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
JPH05506354A (ja) * 1990-02-09 1993-09-22 ザイモジェネティクス，インコーポレイティド 端が切り取られた軽鎖を有する活性プロテインｃ
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5040862A (en) 1990-05-07 1991-08-20 Corning Incorporated Method of trimming optical power
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
JPH07165605A (ja) * 1993-12-16 1995-06-27 Teijin Ltd 活性化プロテインｃバイアル
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (ja) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
AR015598A1 (es) 1997-04-28 2001-05-16 Lilly Co Eli FORMULACIoN LIOFILIZADA QUE COMPRENDE PROTEíNA C ACTIVADA, SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO Y FORMA DE DOSIS UNITARIA QUE LA COMPRENDE.
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
JP2001524111A (ja) 2001-11-27
HK1016472A1 (en) 1999-11-05
DE69828330D1 (de) 2005-02-03
AR012010A1 (es) 2000-09-13
KR100564189B1 (ko) 2006-03-27
AR015598A1 (es) 2001-05-16
PT875252E (pt) 2005-03-31
TR199902529T2 (xx) 2000-02-21
EP0875252B1 (en) 2004-12-29
PL336420A1 (en) 2000-06-19
EP0875252A2 (en) 1998-11-04
EP0875563A3 (en) 2000-08-02
ID23172A (id) 2000-03-23
ZA983496B (en) 1999-10-25
CA2287267A1 (en) 1998-11-05
AU7161898A (en) 1998-11-24
AU743531B2 (en) 2002-01-31
NO995198L (no) 1999-10-25
CO4950523A1 (es) 2000-09-01
HUP0003401A2 (hu) 2001-02-28
CA2288143A1 (en) 1998-11-05
CA2288143C (en) 2012-08-21
SV1998000050A (es) 1999-01-13
BR9809304A (pt) 2000-10-17
HUP0100284A3 (en) 2003-08-28
TWI242443B (en) 2005-11-01
TW585871B (en) 2004-05-01
JP2001527543A (ja) 2001-12-25
SI0875252T1 (en) 2005-06-30
HU224826B1 (en) 2006-02-28
ES2234072T3 (es) 2005-06-16
CN1254284A (zh) 2000-05-24
CO4940438A1 (es) 2000-07-24
CN1235638C (zh) 2006-01-11
EG23685A (en) 2007-05-09
JP4383546B2 (ja) 2009-12-16
HUP0100284A2 (hu) 2001-06-28
EP0875252A3 (en) 2000-07-26
UA73071C2 (en) 2005-06-15
NO995198D0 (no) 1999-10-25
PL195090B1 (pl) 2007-08-31
KR20010020242A (ko) 2001-03-15
EA002149B1 (ru) 2001-12-24
EA199900979A1 (ru) 2000-06-26
EA199900980A1 (ru) 2000-04-24
SV1998000051A (es) 1998-12-11
CZ381099A3 (cs) 2000-03-15
IL132502A0 (en) 2001-03-19
KR20010020325A (ko) 2001-03-15
MY120984A (en) 2005-12-30
HUP0003401A3 (en) 2003-01-28
DK0875252T3 (da) 2005-04-25
DE69828330T2 (de) 2005-10-13
EP0875563A2 (en) 1998-11-04
UA55448C2 (uk) 2003-04-15
AU740753C (en) 2002-10-10
NZ337828A (en) 2001-06-29
BR9809304B1 (pt) 2011-02-08
EA004881B1 (ru) 2004-08-26
WO1998048818A1 (en) 1998-11-05
CN1227025C (zh) 2005-11-16
ATE285788T1 (de) 2005-01-15
TR199902631T2 (xx) 2000-01-21
US6436397B1 (en) 2002-08-20
MY118591A (en) 2004-12-31
IL132325A (en) 2005-07-25
IL132325A0 (en) 2001-03-19
IN183798B (enExample) 2000-04-15
PL336889A1 (en) 2000-07-17
US6159468A (en) 2000-12-12
PL195642B1 (pl) 2007-10-31
IN187157B (enExample) 2002-02-16
PE86299A1 (es) 1999-09-17
ZA983497B (en) 1999-10-25
JP4383547B2 (ja) 2009-12-16
CN1261280A (zh) 2000-07-26
AU7258998A (en) 1998-11-24
KR100450856B1 (ko) 2004-10-02
WO1998048822A1 (en) 1998-11-05
CA2287267C (en) 2006-08-15
US6395270B1 (en) 2002-05-28
CZ298429B6 (cs) 2007-10-03
PE84799A1 (es) 1999-09-16
NZ500346A (en) 2001-08-31
NO995134L (no) 1999-12-21
AU740753B2 (en) 2001-11-15
NO995134D0 (no) 1999-10-21
US6162629A (en) 2000-12-19
BR9809292A (pt) 2000-07-04

Similar Documents

Publication Publication Date Title
ID22933A (id) Fomulasi protien c terakivasi
NO20003303L (no) Vaksine
DE69839603D1 (de) Zierenden proteins
ATA93198A (de) Fluoxetinpellets
ID23173A (id) Turunan pirol trisiklik atau pirazol
DE69808855D1 (de) Klebstoff
DE59802134D1 (de) Einknüpflager
DE69818756D1 (de) Aufwickelspulenverriegelungsmechanismus
DE69801399D1 (de) Urladen
DE69806878D1 (de) Etikettiereinrichtung
ATE236897T1 (de) 3-benzylpiperidine
ATA112597A (de) Snowboard - bindung
PT1015447E (pt) Derivado piperidinilmetiloxazolidinona
FI974129L (fi) Apuväline
ATA86797A (de) Verschleissschuh
KR980000298U (ko) 단추
BR9701194A (pt) Hidrociclo
ATA46498A (de) Kunststoffgleitbahn
LU90081B1 (fr) Serti plaque-clou
SE9700194D0 (sv) Hjälpmedel
NO970759D0 (no) Hjelpemiddel
FI3205U1 (fi) Teline
KR980000299U (ko) 단추
FI972731A0 (fi) Baerande grundelement
BR9700328A (pt) Conjunto tampa-recipiente